SEARCH

SEARCH BY CITATION

References

  • 1
    Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med. 1997; 3: 12851289.
  • 2
    Franzoso G, Carlson L, Xing L, et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 1997; 11: 34823496.
  • 3
    Soysa NS, Alles N. NF-κB functions in osteoclasts. Biochem Biophys Res Commun. 2009; 378: 15.
  • 4
    Vaira S, Johnson T, Hirbe AC, et al. RelB is the NF-kB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci USA. 2008; 105: 38973902.
  • 5
    Tucker E, O'Donnell K, Fuchsberger M, et al. A novel mutation in the Nfkb2 gene generates an NF-κB2 “super repressor”. J Immunol. 2007; 179: 75147522.
  • 6
    Shinkura R, Kitada K, Matsuda F, et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-κB-inducing kinase. Nat Genet. 1999; 22: 7477.
  • 7
    Yin L, Wu L, Wesche H, et al. Defective lymphotoxin-b receptor-induced NF-κB transcriptional activity in NIK-deficient mice. Science. 2001; 291: 21622165.
  • 8
    Novack DV, Yin L, Hagen-Stapleton A, et al. The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med. 2003; 198: 771781.
  • 9
    Guo F, Tanzer S, Busslinger M, Weih F. Lack of nuclear factor-κB2/p100 causes a RelB-dependent block in early B lymphopoiesis. Blood. 2008; 112: 551559.
  • 10
    Ishikawa H, Carrasco D, Claudio E, Ryseck RP, Bravo R. Gastric hyperplasia and increased proliferative responses of lymphocytes in mice lacking the COOH-terminal ankyrin domain of NF-κB2. J Exp Med. 1997; 186: 9991014.
  • 11
    Alles N, Soysa NS, Hussain MD, et al. Polysaccharide nanogel delivery of a TNF-α and RANKL antagonist peptide allows systemic prevention of bone loss. Eur J Pharm Sci. 2009; 37: 8388.
  • 12
    Saito H, Kojima T, Takahashi M, et al. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis Rheum. 2007; 56: 11641174.
  • 13
    Hussain Mian A, Saito H, Alles N, Shimokawa H, Aoki K, Ohya K. Lipopolysaccharide-induced bone resorption is increased in TNF type 2 receptor-deficient mice in vivo. J Bone Miner Metab. 2008; 26: 469477.
  • 14
    Soysa NS, Alles N, Shimokawa H, Jimi E, Aoki K, Ohya K. Inhibition of the classical NF-κB pathway prevents osteoclast bone-resorbing activity. J Bone Miner Metab. 2009; 27: 131139.
  • 15
    Saito H, Soysa N, Alles N, Aoki K, Ohya K. Three-Dimensional Measurements of Bone Resorption Lacunae Reveal Inhibition of Osteoclast Activity by TNF-α Antagonists In vitro. Dentistry In Japan. 2006; 42: 3537.
  • 16
    Aoki K, Saito H, Itzstein C, et al. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest. 2006; 116: 15251534.
  • 17
    Renard P, Ernest I, Houbion A, et al. Development of a sensitive multi-well colorimetric assay for active NF-κB. Nucleic Acids Res. 2001; 29: E21.
  • 18
    Yamada T, Mitani T, Yorita K, et al. Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-κB-inducing kinase. J Immunol. 2000; 165: 804812.
  • 19
    Xiao G, Harhaj EW, Sun SC. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol Cell. 2001; 7: 401409.
  • 20
    Naumann M, Nieters A, Hatada EN, Scheidereit C. NF-κB precursor p100 inhibits nuclear translocation and DNA binding of NF-κB/rel-factors. Oncogene. 1993; 8: 22752281.
  • 21
    Scheinman RI, Beg AA, Baldwin AS Jr. NF-κB p100 (Lyt-10) is a component of H2TF1 and can function as an IκB-like molecule. Mol Cell Biol. 1993; 13: 60896101.
  • 22
    Sun SC, Ganchi PA, Beraud C, Ballard DW, Greene WC. Autoregulation of the NF-κB transactivator RelA (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. Proc Natl Acad Sci USA. 1994; 91: 13461350.